You are here

Böbrek Nakilli Hastada Mikofenolat Sodyum ile İntihar Girişimi

A Suicide Attempt in a Renal Transplant Patient with Mycophenolate Sodium

Journal Name:

Publication Year:

DOI: 
DOI 10.5262/tndt.2012.1002.17
Abstract (2. Language): 
Solid organ transplant patients have higher suicide rates compared to the general population. It is suggested that the major factor contributing to this is to be on multiple immunosupressive drugs, with some of these drugs directly or as a side effect potentially affecting the neurophysiatric system. Mycophenolate sodium (MPS) is an immunosupressive drug used in transplantation and is considered as a relatively safe, non-nephrotoxic agent with relatively few side effects. Common side effects are related to gastrointestinal (nausea, vomiting and diarrhea) and haemopoietic system (neutropenia and mild anemia). However, data on drug overdose and toxicity is limited. In this paper, we report successful management and outcome of renal transplant patient who had committed suicide by ingesting MPS.
Abstract (Original Language): 
Solid organ nakilli hastalar genel popülasyondan daha yüksek intihar oranına sahiptir. Bu durum çoklu immünsupresif ilaç kullanımı ve bu ilaçların nöropsikiyatrik sistem üzerine direkt etkileri ya da yan etkileri ile açıklanmaktadır. Mikofenolat sodyum (MPS) organ naklinde kullanılan güvenilir, nefrotoksisitesi olmayan ve az yan etkiye sahip bir ilaçtır. Yaygın yan etkileri gastrointestinal sistem (bulantı, kusma ve ishal) ve hemopoetik sistem (nötropeni, hafif anemi) ile ilişkilidir. Ancak yüksek doz alım ve toksisitesi ilgili veriler sınırlıdır. Biz bu yazıda, MPS ile intihar girişiminde bulunan böbrek nakilli bir olgunun tedavi ve takibini sunuyoruz
193-194

REFERENCES

References: 

1. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port
FK: Long-term survival in renal transplant recipients with graft
function. Kidney International 2000; 57 (1): 307
2. Halloran PF: Immunosuppressive drugs for kidney transplantation.
N Engl J Med 2004; 351 (26): 2715-2729
3. Ponticelli C, Passerini P: Gastrointestinal complications in renal
transplant recipients. Transpl Int 2005; 18 (6): 643-650
4. Bebarta VS, Heard K, Nadelson C: Lack of toxic effects following
acute overdose of cellcept (mycophenolate mofetil). J Toxicol Clin
Toxicol 2004; 42 (6): 917-919
5. Wu SW, Chang HR, Lai YR, Lian JD: Non-life-threatening
leukopenia in a renal transplant recipient with acute overdose of
mycophenolate mofetil. Transplant Proc 2008; 40 (10): 3770-3771
6. Golshayan D, Pascual M, Vogt B: Mycophenolic acid formulations
in adult renal transplantation - update on efficacy and tolerability.
Therapeutics and Clinical Risk Management 2009; 5: 341-351
7. Sollinger HW, Sundberg AK, Leverson G, Voss BJ, Pirsch JD:
Mycophenolate mofetil versus enteric-coated mycophenolate
sodium: A large, single-center comparison of dose adjustments and
outcomes in kidney transplant recipients. Transplantation 2010; 89
(4): 446-451

Thank you for copying data from http://www.arastirmax.com